THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,329 | -23.1% | 154 | -7.8% | 0.00% | – |
| Q2 2023 | $1,728 | -10.0% | 167 | -5.6% | 0.00% | – |
| Q1 2023 | $1,920 | -67.2% | 177 | -66.0% | 0.00% | – |
| Q4 2022 | $5,846 | +16.9% | 521 | +15.8% | 0.00% | – |
| Q3 2022 | $5,000 | +25.0% | 450 | +2.0% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 441 | -10.7% | 0.00% | – |
| Q1 2022 | $5,000 | +66.7% | 494 | +59.9% | 0.00% | – |
| Q4 2021 | $3,000 | +200.0% | 309 | +99.4% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 155 | -3.1% | 0.00% | – |
| Q2 2021 | $2,000 | -71.4% | 160 | -55.3% | 0.00% | – |
| Q1 2021 | $7,000 | +600.0% | 358 | +336.6% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 82 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 82 | +39.0% | 0.00% | – |
| Q2 2020 | $1,000 | -80.0% | 59 | -70.5% | 0.00% | -100.0% |
| Q2 2018 | $5,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |